Cancer Research Audrey Hepburn EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Ip, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Ip, C.
[Cancer Research 64, 19-22, January 1, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Prostate Specific Antigen Expression Is Down-Regulated by Selenium through Disruption of Androgen Receptor Signaling

Yan Dong1, Soo Ok Lee23, Haitao Zhang1, James Marshall1, Allen C. Gao23 and Clement Ip1

1Departments of Cancer Prevention and Population Sciences, 2Medicine, and 3Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
A previous controlled intervention trial showed that selenium supplementation was effective in reducing the incidence of prostate cancer. Physiological concentrations of selenium have also been reported to inhibit the growth of human prostate cancer cells in vitro. The present study describes the observation that selenium was able to significantly down-regulate the expression of prostate-specific antigen (PSA) transcript and protein within hours in the androgen-responsive LNCaP cells. Decreases in androgen receptor (AR) transcript and protein followed a similar dose and time response pattern upon exposure to selenium. The reduction of AR and PSA expression by selenium occurred well before any significant change in cell number. With the use of a luciferase reporter construct linked to either the PSA promoter or the androgen responsive element, it was found that selenium inhibited the trans-activating activity of AR in cells transfected with the wild-type AR expression vector. Selenium also suppressed the binding of AR to the androgen responsive element site, as evidenced by electrophoretic mobility shift assay of the AR-androgen responsive element complex. In view of the fact that PSA is a well-accepted prognostic indicator of prostate cancer, an important implication of this study is that a selenium intervention strategy aimed at toning down the amplitude of androgen signaling could be helpful in controlling morbidity of this disease.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Prostate cancer is the second most common cancer as well as the second most common cause of cancer death in men in the United States. Every year, there are ~190,000 new cases and 30,000 deaths from prostate cancer (1) . Age is a major risk factor; the incidence is 1 in 53 for men in their 50s but 1 in 7 for men from 60 to 80 years of age. A chemopreventive modality that can suppress or delay the clinical symptoms of prostate cancer would be well suited for preserving the quality of life in high-risk elderly men. In a previous randomized, placebo-controlled cancer prevention trial in which prostate cancer was evaluated as a secondary end point (974 of the 1312 subjects in the cohort were men), supplementation with a nutritional dose of selenium was found to reduce prostate cancer incidence by 50% (2 , 3) . Recent studies by Dong et al. (4) showed that selenium inhibited human prostate cancer cell growth, blocked cell cycle progression at multiple transition points, and induced programmed cell death. Prostate specific antigen (PSA) is a gene known to be under the control of the androgen receptor (AR) and is a well-accepted marker for the diagnosis and prognosis of prostate cancer. In view of the clinical observation of the effectiveness of selenium in prostate cancer prevention, it is reasonable to believe that selenium might be able to reduce the expression of PSA. If confirmed, this attribute obviously has the advantage of forecasting the responsiveness to selenium intervention. In this report, we describe a series of experiments that were designed to test the hypothesis that selenium is capable of down-regulating PSA through a mechanism of attenuating the functional intensity of the AR signal transduction pathway.

As discussed previously (4) , cultured prostate cells respond poorly to selenomethionine (a commonly used selenium reagent) and only when it is present at supraphysiological levels in the medium. A plausible explanation is that prostate cells have a low capacity in metabolizing selenomethionine to methylselenol (CH3SeH), which is believed to be the active species for selenium chemoprevention (5) . This process normally takes place in the liver and kidney. For this reason, methylseleninic acid (CH3SeO2H, abbreviated to MSA) was developed by Ip et al. (6) specifically for in vitro experiments. Once taken up by cells, MSA is readily reduced by glutathione and NADPH to methylselenol (which is rather unstable in itself) via a non-enzymatic reaction. The cellular and molecular responses of prostate cells to physiological concentrations of MSA have been documented in a number of publications (4 , 7, 8, 9, 10) . Thus, we believe we have the right tool to study the effect of selenium on AR signaling.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Selenium Reagent, Prostate Cell Culture, and Cell Growth Analysis.
MSA was synthesized as described previously (6) . The LNCaP human prostate cancer cells were obtained from American Type Culture Collection (Manassas, VA). The cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 units/ml of penicillin, and 100 µg/ml of streptomycin (11) . In some experiments, cells were cultured in an androgen-defined condition by using charcoal-stripped FBS in the presence of 10 nM R1881 (a potent synthetic androgen). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed 24, 48, or 72 h after MSA treatment as described previously (11) . For the quantitative determination of AR and PSA transcripts and proteins, cells were exposed to MSA for much shorter periods of time, usually 24 h or less. Total RNA and protein were isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA).

Real-Time Reverse Transcription-PCR.
First-strand cDNA was synthesized from 100 ng of total RNA by SuperScript II reverse transcriptase (Invitrogen) following the manufacturer’s protocol. The PCR primers and TaqMan probes for ß-actin, AR, and PSA were Assays-on-Demand products from Applied Biosystems. Two µl of first-strand cDNA were mixed with 25 µl of 2x Taqman Universal PCR Master Mix (Applied Biosystems) and 2.5 µl of 20x primers/probe mixture in a 50-µl final volume. Temperature cycling and real-time fluorescence measurement were performed using an ABI prism 7700 Sequence Detection System (Applied Biosystems). The PCR conditions were as follows: an initial incubation at 50°C for 2 min, then a denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

The relative quantitation of gene expression was performed using the comparative CT ({Delta}{Delta}CT) method (12) . Briefly, the threshold cycle number (CT) was obtained as the first cycle at which a statistically significant increase in fluorescence signal was detected. Data normalization was carried out by subtracting the CT value of ß-actin from that of the target gene. The {Delta}{Delta}CT was calculated as the difference of the normalized CT values ({Delta}CT) of the treatment and control samples: {Delta}{Delta}CT = {Delta}CT treatment - {Delta}CT control. Finally, {Delta}{Delta}CT was converted to fold of change by the following formula: Fold of change = 2-{Delta}{Delta}CT.

Western Blot Analysis.
Details of the procedure were described previously (4) . Immunoreactive bands were quantitated by volume densitometry and normalized against either glyceraldehyde-3-phosphate dehydrogenase or {alpha}- actin. The following monoclonal antibodies were used (source): anti-glyceraldehyde-3-phosphate dehydrogenase (Chemicon, Temecula, CA), anti-{alpha}-actin (Sigma Chemical Co., St. Louis, MO), anti-AR (BD Transduction Laboratory, San Jose, CA), and anti-PSA (Santa Cruz Biotechnology, Santa Cruz, CA).

Transfection and Luciferase Assay.
An aliquot of 3 x 105 cells was placed in a 6-well plate and then transfected with a total amount of 5 µg of DNA using Superfect (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Two different constructs were evaluated: the PSA promoter-luciferase reporter plasmid (13) and the androgen responsive element (ARE)-luciferase reporter plasmid (14) . The total amount of plasmid DNA was normalized to 5 µg/well by the addition of empty plasmid. The DNA/liposome mixture was removed 3 h later, and cells were treated with different concentrations of MSA in the presence of 10 nM R1881. Cell extracts were obtained after 24 h, and luciferase activity was assayed using the Luciferase Assay System (Promega, Madison, WI). Protein concentration in cell extracts was determined by the Coomassie Plus protein assay kit (Pierce, Rockford, IL). Luciferase activities were normalized by the protein concentration of the sample. All transfection experiments were performed in triplicate wells and repeated at least four times.

Nuclear Lysate Preparation.
Nuclear protein extract was prepared as described previously (15) . Cells were harvested, washed with PBS twice, and resuspended in a hypotonic buffer [10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, and 0.1% NP40] and incubated on ice for 10 min. Nuclei were precipitated with 3000 x g centrifugation at 4°C for 10 min. After washing once with the hypotonic buffer, the nuclei were lysed in a lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 1% Triton X-100] and incubated on ice for 30 min. The nuclear lysate was precleared by 20,000 x g centrifugation at 4°C for 15 min. Protein concentration was determined by the Coomassie Plus protein assay kit.

Electrophoretic Mobility Shift Assay (EMSA).
A quantity of 20 µg of nuclear protein extract was incubated in a 20-µl solution containing 10 mM HEPES (pH 7.9), 80 mM NaCl, 10% glycerol, 1 mM DTT, 1 mM EDTA, 100 µg/ml poly(deoxyinosinic-deoxycytidylic acid), and the radiolabeled double-stranded AR consensus binding motif 5'-CTAGAAGTCTGGTACAGGGTGTTCTTTTTGCA-3' (Santa Cruz Biotechnology). The protein-DNA complexes were resolved on a 4.5% nondenaturing polyacrylamide gel containing 2.5% glycerol in 0.25x Tris-borate EDTA at room temperature, and the results were autoradiographed. Quantitation of AR DNA-binding activity in the "protein-DNA" bandshift was measured using the Molecular Imager FX System (Bio-Rad, Hercules, CA). For the supershift experiment, 20 µg of cell extract protein were incubated with the monoclonal AR antibody (Santa Cruz Biotechnology) for 1 h at 4°C before incubation with the radiolabeled probe.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
MSA Inhibits LNCaP Cell Growth in a Dose- and Time-dependent Manner.
Table 1Citation shows the results of the effect of MSA treatment on cell growth. The data are expressed as percentages of the untreated control. A concentration of 2.5 µM MSA produced essentially no change, even after 3 days of treatment. Increasing the concentration of MSA to 5 µM inhibited cell growth by about 25%, but the effect was not observed until the 72-h time point. The same magnitude of growth inhibition was observed at 24 h with 10 µM MSA, and by 72 h, there were 50% fewer cells compared with the untreated culture. The experiment therefore established the dose and time response to MSA with respect to growth inhibition. This information is important because the down-regulation of PSA and AR by selenium occurs well before the onset of growth inhibition (see below).


View this table:
[in this window]
[in a new window]

  		Table 1 Effect of MSA on the accumulation of LNCaP cellsa

 
MSA Suppresses PSA mRNA and Protein Expression in LNCaP Cells.
The modulation of PSA mRNA by MSA was assessed quantitatively by real-time RT-PCR. Cells were treated with 10 µM MSA for various lengths of time; the PSA results are shown in Fig. 1ACitation . A marked decrease in PSA mRNA was detected as early as 2 h after exposure to MSA; the mRNA level dropped to <10% of the control value by 6 and 15 h. As shown in Fig. 1BCitation , the depression of PSA mRNA was dependent on the concentration of MSA in the range between 2.5 and 10 µM; the assay was performed after exposure to MSA for 15 h. As little as 2.5 µM MSA reduced PSA mRNA level by 40%. This level of MSA had no effect on cell growth. Even with 10 µM MSA, the near complete elimination of PSA mRNA expression occurred before there was any detectable change in growth. The decrease in PSA protein level by MSA at 15 h, as determined by Western blot analysis, is shown in Fig. 1CCitation ,left panel. The right panel shows the normalized quantitative changes compared with the control value of 100%. Small decreases in PSA protein were evident with 1 or 2.5 µM MSA. At 5 or 10 µM MSA, the level of PSA protein became very low or hardly detectable. The experiments described in Fig. 1Citation were done with cells cultured in 10% FBS. In addition, we carried out another set of experiments with cells cultured in charcoal-stripped FBS containing 10 nM R1881 (a potent synthetic androgen). The down-regulation of PSA mRNA by MSA, as a function of dose and time, was qualitatively similar to that observed with the FBS culture (data not shown).



View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Effect of MSA on PSA expression. A and B, changes in PSA mRNA, as determined by quantitative RT-PCR, as a function of time of treatment with MSA or as a function of MSA concentration. With the exception of the 1-h and the 1 µM MSA data points, the remaining data points are significantly different (P < 0.01) from the control, which is set as 100%. Bars, SE. C, Western blot data of changes in PSA protein level as a function of different concentrations of MSA (left side) and normalized quantitative changes compared with the control value of 100% (right side).

 
MSA Suppresses AR mRNA and Protein Expression in LNCaP Cells.
The expression of PSA is known to be regulated by AR, which is a ligand-activated transcription factor. Our next step was to investigate the expression of AR mRNA in response to MSA by real-time RT-PCR. Fig. 2ACitation shows the time course of response to 10 µM MSA. Within the first hour, there was a 50% decrease in AR mRNA. The transcript level continued to drop down to 20% or below with longer treatment with MSA. The dose response to MSA is shown in Fig. 2BCitation ; these assays were done at the 15-h time point. Interestingly, 1 µM MSA actually increased slightly the level of AR mRNA. However, raising the concentration of MSA to 2.5 µM or above caused a very significant depression of the AR transcript to 40% or less of the control value. We next examined AR protein expression in response to 10 µM MSA. As shown in Fig. 2CCitation , MSA down-regulated AR protein level progressively as a function of time over a period of 24 h. Initially, the reduction in protein appeared to lag behind the reduction in transcript by at least 2–3 h. The delay in response might be reflective of the time needed for protein turnover. Fig. 2DCitation shows the effect of different concentrations of MSA on expression of the AR protein. MSA produced a graded suppression of the AR protein in a dose-dependent manner. In general, the changes in protein level were consistent with the real-time RT-PCR results with the exception of the 1 µM MSA data point.



View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Effect of MSA on AR expression. A and B, change in AR mRNA, as determined by quantitative RT-PCR, as a function of time of treatment with MSA or as a function of MSA concentration. All of the data are significantly different (P < 0.01) from the control, which is set as 100%. Bars, SE. C, Western blot data of changes in AR protein level as a function of time of treatment with 10 µM MSA. D, Western blot data of changes in AR protein level as a function of different concentrations of MSA. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

 
MSA Inhibits AR trans-Activating Activity.
LNCaP cells have a mutant but functional AR. In an attempt to determine the ability of MSA to interfere with AR trans-activating activity, we transiently transfected LNCaP cells with an expression vector for the wild-type AR and the PSA promoter-luciferase reporter plasmid. This region of the PSA regulatory element contains the promoter and enhancer and has been demonstrated to be responsive to androgen stimulation (13) . As shown in Fig. 3ACitation , MSA inhibited the luciferase reporter in a dose-dependent manner. Thus, the PSA promoter activity was decreased by 50, 67, 93, or 96% in the presence of 1, 2, 5, or 10 µM MSA, respectively.



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Effect of MSA on PSA promoter activity (A) and ARE promoter activity (B). The cells were cultured in charcoal-stripped FBS containing 10 nM R1881. The results are expressed as percentages of untreated control. All of the data points are significantly different (P < 0.01) from the control value. Bars, SE.

 
Activated AR exerts its function by binding to the ARE site. Because the PSA promoter contains many regulatory elements in addition to the ARE, one could argue that the decrease in PSA promoter activity might not necessarily be attributable to a change in AR trans-activating activity. To address this issue, we transiently transfected LNCaP cells with an expression vector for the wild-type AR and the ARE-luciferase reporter plasmid. This construct contains three repeats of the ARE region ligated in tandem to the luciferase reporter (14) . As shown in Fig. 3BCitation , the ARE-luciferase activity was inhibited by 50, 60, or 75% in the presence of 1, 2, or 5 µM MSA, respectively. The result obtained with 10 µM MSA was similar to that with 5 µM MSA.

MSA Decreases Binding of AR to ARE.
To determine whether MSA might reduce the DNA binding activity of the AR protein to the ARE, we performed EMSA using radiolabeled oligonucleotides of the ARE with nuclear extract from LNCaP cells treated for 30 min with various concentrations of MSA. As shown in Fig. 4, A and BCitation , a decrease in AR-ARE complex formation was evident with MSA treatment compared with the untreated control. We can rule out the reduced availability of the AR protein as a contributing factor, because there was no change in AR protein after only 30 min of treatment with MSA (see Fig. 2CCitation ). The specificity of the AR-ARE complex was demonstrated by the supershift assay using an antibody against AR (Fig. 4C)Citation .



View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. A, EMSA results of AR binding to ARE as a function of different concentrations of MSA. B, quantitative determination of the EMSA results. C, supershift of the AR/ARE complex with antibody against AR.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
This report is the first to show that a selenium metabolite is able to down-regulate the expression of PSA in human prostate cancer cells via a mechanism involving disruption of the androgen signal transduction pathway. On the basis of the information from this study, selenium decreases AR transcript and protein and inhibits AR trans-activating activity. Selenium can also diminish the binding of AR to the ARE site. However, we cannot at this time distinguish whether this is attributable to a block in nuclear translocation of the activated AR or a physical interference of AR association with the ARE through modulation of other co-regulators. These various possibilities will be investigated systematically in the future. It is noteworthy that the reduction in AR and PSA expression occurs at least 20 h before any significant decrease in cell number. This kind of bellwether change at the molecular level might be one of the causes underlying the sensitivity of prostate cells to selenium treatment.

In a recent paper, Bhamre et al. (16) reported that although supraphysiological levels of selenomethionine inhibited LNCaP cell growth, selenomethionine did not specifically affect the production of PSA when the results were normalized to the decreased number of viable cells. As explained in the "Introduction," selenomethionine is not a suitable selenium reagent for cell biology studies in vitro, because it is poorly metabolized by cultured epithelial cells to the active monomethylated intermediate. Not surprisingly, many cellular and molecular events that are normally sensitive to modulation by physiological levels of MSA (4 , 7, 8, 9, 10, 11) respond very sluggishly to selenomethionine, and only when it is present at excessively high levels in the medium. Thus, the discrepancy between our study and that of Bhamre et al. (16) can be reconciled by the differences in biochemical reactivity between MSA and selenomethionine.

The clonal expansion of prostate cancer at the early stage is mostly dependent on androgen stimulation. A selenium intervention strategy aimed at dampening the amplitude of androgen signaling could be helpful for controlling prostate cancer in high-risk men. PSA is a well-accepted diagnostic and prognostic biomarker of prostate cancer progression. The down-regulation of PSA by selenium therefore has significant clinical implication. In patients treated with selenium, the monitoring of PSA in the circulation could potentially be evaluated as a barometer to gauge the efficacy of intervention. The benefit might also be extended to the prevention of relapses after endocrine therapy. Recurrent prostate cancer is generally hormone refractory, although the expression of AR is maintained regardless of the clinical stage of the disease (17 , 18) . The fact that PSA continues to be produced by the pathologically advanced cancer suggests that the AR signal transduction pathway is still intact. Several hypotheses have been proposed to explain this phenomenon. Mutations of the AR may enable cells to be sensitized by very low levels of androgens, or perhaps even by non-androgen steroids (19) . Alternatively, the receptor may become promiscuous and can be activated by non-steroidal growth factors and cytokines (20) . Prostate cancer may also adapt to androgen deprivation by increasing the expression of AR through gene amplification (21 , 22) . We have developed a LNCaP subline that is not responsive to androgen but is capable of producing a copious amount of PSA. We are planning to use this cell model to further investigate the role of selenium in AR function when the presence of androgen is no longer required.


   FOOTNOTES
 
Grant support: Department of Defense Postdoctoral Fellowship Award and an AACR-Cancer Research Foundation of America Fellowship in Prevention Research Award (to Y. D.), Grant CA90271 (to A. C. G.) and Grant CA91990 (to C. I.) from the National Cancer Institute, and also in part by Cancer Center Support Grant P30 CA16056 (to R. P. C. I.) from the National Cancer Institute.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Notes: Y. Dong and S. O. Lee contributed equally to this work.

Requests for reprints: Allen C. Gao or Clement Ip, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.

Received 9/ 4/03. Revised 10/17/03. Accepted 11/ 3/03.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Greenlee R. T., Murray T., Bolden S., Wingo P. A. Cancer Statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2001.
  2. Clark L. C., Combs G. F., Turnbull B. W., Slate E. H., Chalker D. K., Chow J., Davis L. S., Glover R. A., Graham G. F., Gross E. G., Krongrad A., Lesher J. L., Park K., Sanders B. B., Smith C. L., Taylor R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. J. Am. Med. Assoc., 276: 1957-1985, 1996.[Abstract/Free Full Text]
  3. Duffield-Lillico A. J., Dalkin B. L., Reid M. E., Turnbull B. W., Slate E. H., Jacobs E. T., Marshall J. R., Clark L. C. Selenium supplementation, baseline plasma selenium and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. Br. J. Urol. Int., 91: 608-612, 2003.
  4. Dong Y., Zhang H., Hawthorn L., Ganther H. E., Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res., 63: 52-59, 2003.[Abstract/Free Full Text]
  5. Ip C., Dong Y., Ganther H. E. New concepts in selenium chemoprevention. Cancer Metastasis Rev., 21: 281-289, 2002.[CrossRef][Medline]
  6. Ip C., Thompson H. J., Zhu Z., Ganther H. E. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res., 60: 2882-2886, 2000.[Abstract/Free Full Text]
  7. Jiang C., Wang Z., Ganther H., Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res., 61: 3062-3070, 2001.[Abstract/Free Full Text]
  8. Wang Z., Jiang C., Lu J. Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol. Carcinogen., 34: 113-120, 2002.[CrossRef][Medline]
  9. Jiang C., Wang Z., Ganther H., Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol. Cancer Ther., 1: 1059-1066, 2002.[Abstract/Free Full Text]
  10. Zu K., Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res., 63: 6988-6995, 2003.[Abstract/Free Full Text]
  11. Dong Y., Ganther H. E., Stewart C., Ip C. Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res., 62: 708-714, 2002.[Abstract/Free Full Text]
  12. Livak L. J., Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-{Delta}{Delta}CT method. Methods, 25: 402-408, 2001.[CrossRef][Medline]
  13. Pang S., Dannul J., Kaboo R., Xie Y., Tso C. L., Michel K., de Kernion J. B., Belldegrun A. S. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res., 57: 495-499, 1997.[Abstract/Free Full Text]
  14. Onate S. A., Boonyaratanakornkit V., Spencer T. E., Tsai S. Y., Tsai M. J., Edwards D. P., O’Malley B. W. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem., 273: 12101-12108, 1998.[Abstract/Free Full Text]
  15. Lin D. L., Whitney M. C., Yao Z., Keller E. T. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res., 7: 1773-1781, 2001.[Abstract/Free Full Text]
  16. Bhamre S., Whitin J. C., Cohen H. J. Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth. Prostate, 54: 315-321, 2003.[CrossRef][Medline]
  17. Sadi M. V., Walsh P. C., Barrack E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer—comparison of receptor content and response to hormonal therapy. Cancer (Phila.), 67: 3057-3064, 1991.
  18. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate, 28: 129-135, 1996.[CrossRef][Medline]
  19. Zhao X. Y., Malloy P. J., Krishnan A. V., Swami S., Navone N. M., Peehl D. M., Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med., 6: 703-706, 2000.[CrossRef][Medline]
  20. Culig Z., Hobisch A., Hittmair A., Peterziel H., Cato A. C. B., Bartsch G., Klocker H. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate, 35: 63-70, 1998.[CrossRef][Medline]
  21. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.[CrossRef][Medline]
  22. Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., Trapman J., Cleutjens K., Noordzij A., Visakorpi T., Kallioniemi O. P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57: 314-319, 1997.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
L. Wang, M. J.L. Bonorden, G.-x. Li, H.-J. Lee, H. Hu, Y. Zhang, J. D. Liao, M. P. Cleary, and J. Lu
Methyl-Selenium Compounds Inhibit Prostate Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate Model with Survival Benefit
Cancer Prevention Research, May 1, 2009; 2(5): 484 - 495.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Tsavachidou, T. J. McDonnell, S. Wen, X. Wang, F. Vakar-Lopez, L. L. Pisters, C. A. Pettaway, C. G. Wood, K.-A. Do, P. F. Thall, et al.
Selenium and Vitamin E: Cell Type- and Intervention-Specific Tissue Effects in Prostate Cancer
J Natl Cancer Inst, March 4, 2009; 101(5): 306 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. Liu, H. Zhang, L. Zhu, L. Zhao, and Y. Dong
Kruppel-Like Factor 4 Is a Novel Mediator of Selenium in Growth Inhibition
Mol. Cancer Res., February 1, 2008; 6(2): 306 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. N. Syed, N. Khan, F. Afaq, and H. Mukhtar
Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2193 - 2203.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Y. Chun, Y. Hu, E. Pinder, J. Wu, F. Li, and A. C. Gao
Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter
Mol. Cancer Ther., September 1, 2007; 6(9): 2572 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
U. Peters, C. B Foster, N. Chatterjee, A. Schatzkin, D. Reding, G. L Andriole, E D. Crawford, S. Sturup, S. J Chanock, and R. B Hayes
Serum selenium and risk of prostate cancer--a nested case-control study
Am. J. Clinical Nutrition, January 1, 2007; 85(1): 209 - 217.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Zhao, F. E. Domann, and W. Zhong
Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3275 - 3284.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Husbeck, R. S. Bhattacharyya, D. Feldman, and S. J. Knox
Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action.
Mol. Cancer Ther., August 1, 2006; 5(8): 2078 - 2085.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Y. Chun, N. Nadiminty, S. O. Lee, S. A. Onate, W. Lou, and A. C. Gao
Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer.
Mol. Cancer Ther., April 1, 2006; 5(4): 913 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. L. Sabichi, J. J. Lee, R. J. Taylor, I. M. Thompson, B. J. Miles, C. M. Tangen, L. M. Minasian, L. L. Pisters, J. R. Caton, J. W. Basler, et al.
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2178 - 2184.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Kohrle, F. Jakob, B. Contempre, and J. E. Dumont
Selenium, the Thyroid, and the Endocrine System
Endocr. Rev., December 1, 2005; 26(7): 944 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Dong, H. Zhang, A. C. Gao, J. R. Marshall, and C. Ip
Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers
Mol. Cancer Ther., July 1, 2005; 4(7): 1047 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Bonham, J. Posakony, I. Coleman, B. Montgomery, J. Simon, and P. S. Nelson
Characterization of Chemical Constituents in Scutellaria baicalensis with Antiandrogenic and Growth-Inhibitory Activities toward Prostate Carcinoma
Clin. Cancer Res., May 15, 2005; 11(10): 3905 - 3914.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. O. Lee, N. Nadiminty, X. X. Wu, W. Lou, Y. Dong, C. Ip, S. A. Onate, and A. C. Gao
Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells
Cancer Res., April 15, 2005; 65(8): 3487 - 3492.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
G. J Beckett and J. R Arthur
Selenium and endocrine systems
J. Endocrinol., March 1, 2005; 184(3): 455 - 465.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. R. Taylor, H. L. Parnes, and S. M. Lippman
Science Peels the Onion of Selenium Effects on Prostate Carcinogenesis
J Natl Cancer Inst, May 5, 2004; 96(9): 645 - 647.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. D. Cho, C. Jiang, B. Malewicz, Y. Dong, C. Y.F. Young, K.-S. Kang, Y.-S. Lee, C. Ip, and J. Lu
Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription
Mol. Cancer Ther., May 1, 2004; 3(5): 605 - 612.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Ip, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Ip, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online